EuroBiotech: More Articles of Note

Newspapers
(NS Newsflash/CC BY 2.0)

> Selvita raised $41 million (€33 million). The Polish drug discovery shop will use the cash to support the advance of its pipeline, including CDK8 kinase cancer candidate SEL120. Statement 

> Galapagos and MorphoSys presented phase 1 data on their atopic dermatitis candidate. Five of the six patients who received the highest dose of the IL-17C antibody experienced a 50% improvement on a disease severity index. A phase 2 trial will start in the coming months. Release

> Acacia Pharma set its IPO price range at €3.60 ($4.40) to €4.60 a share. That values the company at up to €180 million. In 2015, Acacia pulled out of an attempt to raise £150 million in a London IPO. Statement (PDF)

Survey

Share your opinion. Take our five minute survey.

How do you select the most suitable advanced dosage forms for new molecules in your development pipelines? Share your insights in this 5-minute survey. The first 50 qualified respondents will receive a $5 Amazon gift card.

> Arix Bioscience extended its reach into China through an agreement with Fosun. The pact gives Arix’s portfolio companies a route into China, while also providing the investor with a source of opportunities in the country. Release 

> Minoryx Therapeutics spun off its site-directed enzyme enhancement therapy platform to create a new company, Gain Therapeutics. The move frees Minoryx to concentrate on a clinical-phase CNS drug while Gain works to squeeze additional assets out the platform. Statement

> Ascendis Pharma priced a stock offering that will net it around $211 million (€172 million). The Danish drug developer will use the money to advance TransCon Growth Hormone toward the market. Release

Suggested Articles

The FDA rejected the new drug application for golodirsen, the follow-up to Exondys 51, Sarepta’s first treatment for Duchenne muscular dystrophy.

Levi Garraway is set to take up one of the biggest hot seats in biopharma when he becomes the next chief medical officer at Roche.

Vanda Pharmaceuticals received a Complete Response Letter from the FDA taking issue with a small study testing Hetlioz in jet lag disorder.